Our first order of business this morning will be to go back to the options idea we signaled for the BURL chain on Thursday morning, the BURL 03/17 $85-95 Calls. We reported the solid gains that the strong earnings report allowed us on that first day in Friday’s morning report, and today we’ll have to follow up once again to relay the added opportunities we saw to close out the week.
We did caution on Friday that based on premarket activity, our ranges could be extended considerably, and that’s exactly what happened. The updates ranges showing the total moves we seen over a two session span are as follows:
$85 Calls – Range: 5.60-11.13 – Max Gain: 99%
$90 Calls – Range: 2.50-7.35 – Max Gain: 194%
$95 Calls – Range: .71-3.50 – Max Gain: 392%
Galectin Therapeutics, Inc. GALT
GALT is a stock that we began tracking earlier in 2017, including it in our report on January 17th. Shortly following that alert, the stock saw a low of .935 and it hasn’t looked back since.
We followed up with an update of GALT on February 10th, at which time we had seen a relatively modest range of .935 to 1.29 (+38%). We noted that the gains would be “sustainable if GALT can manage to crack past the current 200DMA” (then at 1.32).
That did happen, and on the 15th we posted another followup stating “One more bullish push will get us into double-bagger territory for this idea, and the stock may well make a run into the 2.00-range.” Our assumptions proved spot-on again, as one week later, the stock went on to hit a high of 2.21, representing a total move up from our observed low of .935 amounting to 136%
Once again GALT is heading to highs, this morning trading as high as 2.30 in the premarket on the heels of some positive clinical trial data (>>View PR). We’re going to want to be paying attention to its activity as we open up another trading week, as expectations of extended gains once again do not seem unreasonable.
RNVA, CXRX, PTCT, CCTL, CXRX, PIP